About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Phosphagenics Provides Update on TPM Propofol Development Program

November 9, 2017

Click here to read more

Post navigation

Phosphagenics Mylan Arbitration Hearing Concluded

Phosphagenics Signs a Multinational License for TPM® in Personal Care Products

Related Posts

Receipt of R&D Tax Incentive

November 27, 2018

Phosphagenics Appoints Three New Directors

April 13, 2015

Retirement of Non-Executive Director

May 28, 2018

Recent Posts

Watch now: how significant is chronic insomnia in Australia?
October 14, 2026
Recruitent recommences for phase III insomnia trial
August 31, 2026
Euroz Hartleys | Successful Phase 3 Interim Results
July 8, 2026

Categories

Analyst Coverage
Company Announcement
Company Report
Investor Webinar
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.